Trial Profile
A study evaluating safety and efficacy of Vedolizumab in refractory pediatric Inflammatory Bowel Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Feb 2018
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- 13 Feb 2018 New trial record